By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


SEARCH JOBS



Segment
Start Up

Collaborations

Dyax  Antibody phage display





Company News
Merrimack (MACK) Reports Second Quarter 2016 Financial Results 8/5/2016 7:58:27 AM
Merrimack (MACK) Announces ONIVYDE Regimen Receives Positive CHMP Opinion In European Union 7/25/2016 6:37:09 AM
Merrimack (MACK) Announces Timing Of Second Quarter 2016 Investor Conference Call 7/20/2016 8:00:12 AM
FDA Grants Merrimack (MACK) Fast Track Designation For Seribantumab (MM-121) In Non-Small Cell Lung Cancer 7/6/2016 6:34:23 AM
Merrimack (MACK) Release: NAPOLI-1 Data Demonstrates ONIVYDE Regimen Maintains Quality Of Life While Improving Overall Survival In Patients With Metastatic Pancreatic Cancer 6/30/2016 8:28:51 AM
Merrimack (MACK) To Present New Analyses Of Phase 3 NAPOLI-1 Data At The ESMO 18th World Congress On Gastrointestinal Cancer 6/22/2016 6:05:21 AM
ASCO2016: Merrimack (MACK) Release: Final Analysis Of First-In-Human Phase 1 Study Of MM-151 Shows Positive Clinical Activity In Multiple Solid Tumor Types, Including Colorectal Cancer 6/6/2016 9:17:09 AM
Merrimack (MACK) Announces A Leading-Edge Biomarker-Selected, Multi-Arm Basket Trial That Matches Patients With Most Appropriate Combination Regimens 5/19/2016 9:22:18 AM
Merrimack (MACK) To Present On Extensive Oncology Pipeline At The 2016 ASCO Annual Meeting 5/19/2016 6:59:15 AM
Merrimack (MACK) And Baxalta (BXLT) Announce Initiation Of Phase 1 Study Of MM-151 In Combination With The ONIVYDE (Irinotecan Liposome Injection) Regimen In Metastatic Colorectal Cancer 5/19/2016 6:27:16 AM
12345678910...
//-->